Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-552-4 | CAS number: 976-70-5
Endpoint summary
Administrative data
Key value for chemical safety assessment
Justification for classification or non-classification
Use of therapeutically effective doses of spironolactone can lead to reversible fertility disturbances in humans of both sexes. In so far as such effects are the expression of an anti-androgenic partial effect, corresponding disturbances to sexual function should fundamentally also be taken into consideration following intake of aldona. As a matter of precaution, the risk of a feminizing effect in male offspring should also be assumed if women are burdened with aldona during the sensitive phase of fetal sexual differentiation (from day 45 after conception onwards). After spironolactone, feminizing effects were observed on the external genital organs of male offspring of rats exposed to daily doses of ca. 160 mg/kg body weight during gestation. Animal experiments produced no indication that spironolactone may possess a teratogenic potential beyond this. For humans there is too little experience concerning the safety of using spironolactone during pregnancy. In analogy to spironolactone, exposure of nursing women is fundamentally to be avoided as neither the entry of aldona and/or possible metabolites into the mother's milk nor an inhibition of the milk production can as yet be excluded. A potential risk to the development of the infant has thus to be assumed.
According to the Directive 67/548/EEC, aldona is classified:
Category 2; R60- May impair fertility.
Category 2; R61 - Possible risk of harm to the unborn child.
Classified as Category 1B according to Regulation (EC) 1272/2008 (CLP).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
